Therefore, to determine the associations of TNF inhibitor use with kidney and survival outcomes in IBD, we used a large nationwide cohort of US veterans with comprehensive patient-level clinical data and investigated the association of incident or new anti-TNF therapy with subsequent risk of kidney disease progression and all-cause mortality in patients with incident IBD, while mitigating confounding by medical indication. The gene discussed is TNF; the disease is kidney disorder.